An experimental drug tested in two large studies: one in primary progressive and one in non-active secondary progressive multiple sclerosis. They check whether it slows the worsening of disability; there are no results yet, and some participants receive a placebo. The European trial register lists Greece as accepting participants for both studies, but each centre must confirm enrolment and eligibility.
What is being studied
Orelabrutinib is an experimental drug designed to inhibit BTK, a protein involved in immune-cell signalling. Zenas BioPharma (USA), LLC sponsors studies of orelabrutinib in primary progressive MS (NCT07067463) and non-active secondary progressive MS (NCT07299019). The studies assess whether treatment affects disability worsening.
Research stage
Large study to confirm benefit and safety
The two trial records list overall recruitment; Greek participation is described separately for each study below.
What we know so far
ClinicalTrials.gov lists both Phase 3 studies overall as accepting participants, with about 705 and 990 planned participants and no posted results (records last updated 10 and 4 November 2026). At the 25 October CTIS check, Greece was listed as accepting participants for PriMroSe, with seven Greek site listings. At the 5 November CTIS check, Greece was also listed as accepting participants for Monarch, with six Greek site listings; earlier, at the 28 October check, Greek recruitment for Monarch had been listed as pending. The ClinicalTrials.gov record for Monarch lists two Greek centres as accepting participants: "Errikos Dunant Hospital" in Athens (the Henry Dunant Hospital Center) and "Metropolitan General Hospital" in Cholargos (Metropolitan General). The EU register does not show which of its listed Greek centres have started, and no recruitment start date for Greece has been entered there for either study. Neither source establishes benefit, safety, myelin repair, an available place or individual eligibility at a Greek centre.
What this means for patients today
A person with primary progressive MS may wish to discuss PriMroSe because it tests whether orelabrutinib can delay disability progression; taking part helps answer that question. No PriMroSe results are posted, and participants are assigned to orelabrutinib or placebo, so neither receiving the experimental drug nor personal benefit is assured. At the 25 October CTIS check, Greece was listed as accepting participants for PriMroSe. A person with non-active secondary progressive MS may wish to ask about the separate Monarch study, which also compares orelabrutinib with placebo and has no posted results: the EU register now lists Greece as accepting participants, and ClinicalTrials.gov lists two centres, "Errikos Dunant Hospital" in Athens (the Henry Dunant Hospital Center) and "Metropolitan General Hospital" in Cholargos (Metropolitan General), as accepting participants. An individual centre must confirm current enrolment, available places and eligibility; study access is not approved treatment or evidence of Greek commercial availability or reimbursement. No established approved treatment has been proven to reliably restore myelin in MS.
PriMroSe — primary progressive MS
At its 25 Oct 2026 check, the EU trial register listed Greece as accepting participants for this study and included seven Greek site listings. No per-site recruitment status, available place or individual eligibility was shown in that register. Confirm current participation with the relevant centre. The ClinicalTrials.gov record lists overall recruitment but no Greek location rows; that absence applies only to that record.
Chaidari
University General Hospital Attikon General Hospital Of West Attica H Agia Varvara
At its 5 Nov 2026 check, the EU trial register listed Greece as accepting participants for this study and included six Greek site listings. No per-site recruitment status, available place or individual eligibility was shown in that register. Confirm current participation with the relevant centre. The ClinicalTrials.gov record, updated 4 Nov 2026, lists "Errikos Dunant Hospital" in Athens (postcode 115 26) and "Metropolitan General Hospital" in Cholargos (postcode 155 62) as accepting participants; these match the Henry Dunant Hospital Center and Metropolitan General listed below. The two registers were updated on different dates.
Orelabrutinib — an experimental treatment for progressive MS
Where the study is running
CTIS checks: PriMroSe (25 October 2026) — Greece accepting participants, seven Greek site listings; Monarch (5 November 2026) — Greece accepting participants, six Greek site listings. For neither study does CTIS show a recruitment status for each site or a recruitment start date for Greece. The ClinicalTrials.gov records list no Greek location for PriMroSe (last updated 10 November 2026) and two for Monarch (updated 4 November 2026): "Errikos Dunant Hospital", Athens, and "Metropolitan General Hospital", Cholargos, both listed as accepting participants; they match the Henry Dunant Hospital Center and Metropolitan General in the CTIS list.
NCT07067463, for primary progressive MS, was updated on 22 September 2026 and plans about 705 participants. NCT07299019, for non-active secondary progressive MS, was updated on 23 September 2026 and plans about 990 participants. Both Phase 3 studies, sponsored by Zenas BioPharma (USA), LLC, are listed as accepting participants. Neither registry record has posted results. These dates mark registry updates, not the start of the studies or recruitment.